Pharmaceuticals & Biotech U.S. Community

Cue Biopharma bets its future on a new allergy drug designed by the same scientist who created Xolair, aiming to make treatment far less frequent for people with chronic hives and other allergic conditions. A key mid-stage trial result is coming soon, and it could either put Cue on big pharma’s radar or expose just how risky this turnaround really is.Read more

Zoetis makes medicines for pets and farm animals, but a sharp slowdown in its US pet business recently rattles investors and raises questions about how durable demand really is. The story hinges on whether its long track record of steady pricing and buybacks can keep the business resilient—or whether debt, product concentration, and copycat drugs start to bite.Read more

Early trial results in a pancreatic cancer vaccine show most patients mounting a strong immune response, raising hopes it could help keep the disease from coming back after treatment. The next big readout could be a turning point if the larger study confirms the benefit—and a setback if it doesn’t.Read more

Arcturus Therapeutics’ biggest vaccine partner has soured on their relationship, and that fallout could unexpectedly free the company to team up with new pharma giants. The story digs into why this breakup matters, what new partners like Sanofi or BioNTech might want from Arcturus’ RNA platform, and what could still derail the upside.Read more

This company’s main dialysis infection product still looks hard to replace, but the market seems to be pricing it as if growth has stalled for good. A pricing change and two upcoming trial readouts could reshape the story quickly, with big upside if things go right—and a clear hit if they don’t.Read more

Catalysts Recent success in a phase IIIa trial showed once-daily doses of oral semaglutide demonstrated a statistically significant and superior reduction in HbA1c by 0.83% versus placebo at 26 weeks for adolescents with Type II diabetes. Based on the study data, NVO intends to seek regulatory approval for oral semaglutide in adolescents aged 10 to 17 with T2D for both Rybelsus and oral Ozempic in the U.S. and the EU in the second half of the year.Read more

RXRX is a terrible biotech only because the INSIDERS themselves don’t believe in it! All they’re doing is milking the heck out of this doomed stock!Read more

Eli Lilly’s weight-loss and diabetes medicines keep driving rapid growth, and a new treatment in late-stage testing could make that lead even bigger. The catch is that tougher competition and tighter drug pricing could squeeze profits, so the next round of trial and approval news matters.Read more

High Tide is turning its cannabis stores into something closer to a membership-and-data business, using staff incentives and word of mouth to bring in loyal customers. As that membership base grows, its sales insights become more valuable to growers, which could help it keep winning customers and taking share—if the flywheel keeps spinning.Read more